NCT06162377 2025-12-17Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.M.D. Anderson Cancer CenterPhase 4 Recruiting25 enrolled
NCT01004393 2016-02-02Methylnaltrexone for Opioid-induced Constipation in Cancer PatientsUniversity of VermontPhase 2 Completed12 enrolled 10 charts